Literature DB >> 12109786

A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice.

Kazuo Ohba1, Katsuhisa Omagari, Kunihiko Murase, Hiroaki Hazama, Jun-Ichi Masuda, Hideki Kinoshita, Hajime Isomoto, Yohei Mizuta, Masanobu Miyazaki, Ikuo Murata, Shigeru Kohno.   

Abstract

AIMS: MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop lymphadenopathy, hypergammaglobulinaemia, serum auto-antibodies, and a generalised auto-immune disease including glomerulonephritis and arthritis, and have been used as a model for the study of systemic lupus erythematosus. Recently, MRL/lpr mice were also reported as a potentially suitable animal model of primary biliary cirrhosis (PBC). The aim of this study was to determine the suitability of MRL/Mp-lpr/lpr (MRL/lpr) mice as an experimental auto-immune-mediated cholangitis model for PBC.
METHODS: We investigated the serum hepatobiliary enzymes, histopathological findings, and the target antigen of antimitochondrial antibodies (AMA) in MRL/lpr mice.
RESULTS: Serum levels of total bilirubin and hepatobiliary enzymes including alanine aminotransferase (ALT), leucine aminopeptidase (LAP), and gamma-glutamyl transpeptidase (G-GTP) in older-aged (over 20 weeks old) MRL/lpr or MRL/Mp-+/+ (MRL/+) mice were not significantly higher than those in younger (8-12 weeks old) MRL/lpr, MRL/+, or older-aged control mice (C3H/HeJ and BALB/C mice). Histopathologically, 24 of 47 (51%) older-aged MRL/lpr mice showed evidence of cholangitis, compared with two of 20 (10%) younger MRL/lpr mice. Especially, epithelioid granuloma and/or bile duct loss were seen in 11 out of 47 (23%) older-aged MRL/lpr mice, whereas such findings were seen in only one of 20 (5%) younger MRL/lpr mice. None of the MRL/+, C3H/HeJ, and BALB/C mice developed cholangitis. The target antigens of AMA were not pyruvate dehydrogenase complex but 2-oxoglutarate dehydrogenase complex and/or branched-chain oxo-acid dehydrogenase complex as confirmed by immunoblotting. There was no significant correlation between the presence of AMA and severity of histological lesions in older-aged MRL/lpr mice, and there were no significant differences in these biochemical data, the proportion of mice with portal inflammation, cholangitis and AMA between male and female MRL/lpr mice.
CONCLUSION: Although several clinical features were incompatible with PBC, the serological and histopathological features of MRL/lpr mice indicate that these mice can be used as an experimental immune-mediated cholangitis model for PBC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109786     DOI: 10.1080/00313020220131318

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  6 in total

1.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

2.  Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus.

Authors:  Fan Lian; Yu Wang; Jie Chen; Hanshi Xu; Xiuyan Yang; Liuqin Liang; Zhongping Zhan; Yujin Ye; Minhu Chen
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

Review 3.  Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Peter Fickert
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.

Authors:  Yusuke Nozaki; Kenichi Harada; Takahiro Sanzen; Yasuni Nakanuma
Journal:  Med Mol Morphol       Date:  2013-02-09       Impact factor: 2.309

5.  Pathological features of new animal models for primary biliary cirrhosis.

Authors:  Koichi Tsuneyama; Yuki Moritoki; Kentaro Kikuchi; Yasuni Nakanuma
Journal:  Int J Hepatol       Date:  2011-07-06

Review 6.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.